Acasti Pharma traded at $0.83 this Friday July 1st, decreasing $0.03 or 3.10 percent since the previous trading session. Looking back, over the last four weeks, Acasti Pharma lost 15.60 percent. Over the last 12 months, its price rose by 47.26 percent. Looking ahead, we forecast Acasti Pharma to be priced at 0.81 by the end of this quarter and at 0.76 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Acasti Pharma 0.83 -0.03 -3.10% 47.26%
Addus HomeCare 84.62 1.34 1.61% -4.80%
Agile Therapeutics 0.64 -0.52 -45.03% -52.56%
Amarin 1.44 -0.05 -3.36% -67.20%
BioScrip 28.53 0.74 2.66% 30.33%
Genetic Technologies 1.21 0.05 4.31% -71.05%
Cassava Sciences Inc. 26.51 -1.61 -5.73% -70.56%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%

Acasti Pharma
Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.